NEW YORK, Nov. 3, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Immunogenicity to BiologicsImmunogenicity, the body's response to therapeutic proteins, is vitally important in the development and marketing of biotech drugs. Failure to predict and monitor levels of immunogenicity can have disastrous results for patients and for companies.
This comprehensive new report, written by industry experts, gives you the information you need to understand this vital subject and includes a chapter on the commercial implications written by PricewaterhouseCoopers (PWC).
This unique, 170-page report, edited by Dr Nicole Lyscom, is written by industry experts including:
Dr Stephen Swanson, Department of Clinical Immunology, Amgen
Meena Wadhwa, Cytokines and Growth Factor Section, Biotherapeutics Group
Robin Thorpe, National Institute for Biological Standards and Control, UK
Dr Deborah Finco-Kent, Immunogenicity Assay Coordinator, Pfizer
Dr Ingrid Caras, Preclinical and Clinical Development Sciences, PDL Biopharma
Dr Bonita Rup, Bioanalytical R&D, Drug Safety and Metabolism, Wyeth Research
Dr Christian Schneider, Division EU Cooperation/Microbiology, Paul-Erlich-Institute
PD Harald Kropshofer PhD, Immunosafety of Biologics, F. Hoffman La Roche
And it includes a chapter on the commercial implications written by Jo Pisani and Yann Bonduelle of PwC. It will enable you to:
Contents include:• Factors contributing to immunogenicity
• Impact on safety and ef
Copyright©2010 PR Newswire.
All rights reserved